1. Home
  2. VLY vs IMVT Comparison

VLY vs IMVT Comparison

Compare VLY & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

N/A

Current Price

$14.14

Market Cap

7.8B

Sector

Finance

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

N/A

Current Price

$29.36

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VLY
IMVT
Founded
1927
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
8.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
VLY
IMVT
Price
$14.14
$29.36
Analyst Decision
Buy
Buy
Analyst Count
14
17
Target Price
$16.89
★ $48.88
AVG Volume (30 Days)
★ 6.8M
1.3M
Earning Date
10-22-2026
11-09-2026
Dividend Yield
★ 3.08%
N/A
EPS Growth
★ 46.38
N/A
EPS
★ 0.57
N/A
Revenue
N/A
N/A
Revenue This Year
$12.61
N/A
Revenue Next Year
$20.48
N/A
P/E Ratio
$25.01
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.34
$21.43
52 Week High
$15.20
$45.42

Technical Indicators

Market Signals
Indicator
VLY
IMVT
Relative Strength Index (RSI) 66.03 39.33
Support Level $13.32 $25.83
Resistance Level $15.00 $29.83
Average True Range (ATR) 0.31 1.04
MACD 0.19 0.44
Stochastic Oscillator 88.26 73.81

Price Performance

Historical Comparison
VLY
IMVT

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: